Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data.

ABSTRACT:

Introduction

Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors.

Methods

Headache specialists, cardiologists, and health economics and outcomes researchers convened to identify diagnostic codes for: (1) CV diseases contraindicating triptans based on FDA labeling; (2) conditions comprising "other significant underlying CV disease"; and (3) CV risk factors included as warnings and precautions for triptans. A retrospective, cross-sectional analysis of commercially insured adult US migraine patients in the 2017 Optum^® Clinformatics^® Data Mart (CDM) and the 2017 IBM^® Watson Health

SUBMITTER: Dodick DW 

PROVIDER: S-EPMC7585888 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature